PharmaPoint: Prostate Cancer - Global Drug Forecast and Market Analysis to 2023 - PowerPoint PPT Presentation

View by Category
About This Presentation
Title:

PharmaPoint: Prostate Cancer - Global Drug Forecast and Market Analysis to 2023

Description:

Big Market Research present “PharmaPoint: Prostate Cancer - Global Drug Forecast and Market” Size, Share, Industry Trends, Demand, Analysis, Research, Report, Company Profiles, Forecast to 2023. Visit for more info @ Prostate cancer is the second most common cancer in men worldwide, after skin cancer. It accounts for 15% of all the cancers diagnosed in men, and thus represents a huge burden on healthcare systems. While patients diagnosed with early-stage, localized prostate cancer can be cured, patients who are diagnosed with or progress to castration-resistant prostate cancer (CRPC) have no curative options. – PowerPoint PPT presentation

Number of Views:31

less

Write a Comment
User Comments (0)
Transcript and Presenter's Notes

Title: PharmaPoint: Prostate Cancer - Global Drug Forecast and Market Analysis to 2023


1
PharmaPoint Prostate Cancer
Global Drug Forecast and Market Analysis
to 2023
2
Report Description
Summary Prostate cancer is the second most common
cancer in men worldwide, after skin cancer. It
accounts for 15 of all the cancers diagnosed in
men, and thus represents a huge burden on
healthcare systems. While patients diagnosed with
early-stage, localized prostate cancer can be
cured, patients who are diagnosed with or
progress to castration-resistant prostate cancer
(CRPC) have no curative options. Since 2010,
five new drugs have been approved for the
treatment of CRPC Dendreons Provenge, Sanofis
Jevtana, Johnson Johnsons Zytiga,
Medivation/Astellas Xtandi, and Bayers Xofigo.
During the forecast period from 2013-2023,
GlobalData expects that nine new late-stage
pipeline agents will launch, eight of which will
be for the treatment of CRPC. As a result of this
unprecedented level of clinical development,
GlobalData predicts there will be massive changes
in the CRPC treatment paradigm. In addition, due
to the influx of new therapies, the size of the
prostate cancer market across the nine major
pharmaceutical markets (9MM) (US, France,
Germany, Italy, Spain, UK, Japan, Brazil, and
Canada) will increase three-fold. Read more
details at http//www.bigmarketresearch.com/phar
mapoint-prostate-cancer-global-drug-forecast-and-a
nalysis-to-2023-market
3
Report Description
  • Key Questions Answered
  •  
  • How will prostate cancer disease management
    change as new agents enter the market?
  • Which prostate cancer patients have the greatest
    unmet needs and how well will these needs be
    addressed by the new agents?
  • What are the most dominant players in the
    prostate cancer space and what corporate
    strategies are pursued by these companies?
  • What are the most promising late-stage pipeline
    agents for prostate cancer.How do they compare to
    currently marketed products?
  • What opportunities will remain for future players
    following the launch of these pipeline agents?
  •  

4
Table of Contents
  • Key Findings
  •  
  • The prostate cancer market, in the 9MM is
    forecasted to rapidly increase from 2.6bn in
    2013 to 8.3bn in 2023, at a CAGR of 12.4. This
    growth will be driven by the label extensions of
    currently marketed drugs as well as the launch of
    nine new premium-priced therapies for the
    treatment of prostate cancer.
  • GlobalData expects Medivation and Astellas Xtandi
    will become the market leader in prostate cancer.
    Xtandi is currently approved for pre- and
    post-chemotherapy metastatic castration-resistant
    prostate cancer (CRPC). Over the course of the
    forecast period, GlobalData anticipates it will
    receive label extensions in non-metastatic CRPC
    and hormone-sensitive prostate cancer, making it
    available to virtually all prostate cancer
    patients segments, with the exception of those
    with localized disease.
  • The prostate cancer pipeline is robust with nine
    drugs in late-stage development. While androgen
    biosynthesis is still a major target, many of the
    pipeline candidates have diverse mechanisms of
    action and target proteins and pathways that are
    not targeted by the currently marketed prostate
    cancer treatments. Among these new candidates are
    a checkpoint inhibitor, a clusterin inhibitor,
    and an anti-angiogenic agent.

5
Table of Contents
  • Scope
  •  
  • Overview of prostate cancer, including
    epidemiology, etiology, pathophysiology, clinical
    staging, symptoms, prognosis, quality of life,
    and disease management.
  • Annualized prostate cancer therapeutics market
    revenue from 2013-2023. Annual cost of therapy,
    and major marketed and pipeline drug sales in
    this forecast period are included.
  • Key topics covered include strategic competitor
    assessment, market characterization, unmet needs,
    and implications for the prostate cancer
    therapeutics market.
  • Pipeline analysis The prostate cancer pipeline
    is robust with many late-stage candidates set to
    launch in the forecast period. Comprehensive
    analysis of the nine most promising candidates in
    Phase III development are highlighted and
    profiled.
  • Analysis of the current and future market
    competition in the global prostate cancer
    therapeutics market, including insightful review
    of the key industry drivers, restraints and
    challenges. Each trend is independently
    researched to provide qualitative analysis of its
    implications.

6
Table of Contents
  • Reasons to buy
  •  
  • Develop and design your in-licensing and
    out-licensing strategies through a review of
    pipeline products and technologies, and by
    identifying the companies with the most robust
    pipeline.
  • Develop business strategies by understanding the
    trends shaping and driving the 9MM prostate
    cancer market.
  • Drive revenues by understanding the key trends,
    innovative products and technologies, market
    segments, and companies likely to impact the 9MM
    prostate cancer therapeutics market in the
    future.
  • Formulate effective sales and marketing
    strategies by understanding the competitive
    landscape and by analysing the performance of
    various competitors.
  • About Report http//www.bigmarketresearch.com/rep
    ort-enquiry/308046

7
FOR MORE DETAILS
Visit us at
http//www.bigmarketresearch.com/pharmapoint-prost
ate-cancer-global-drug-forecast-and-analysis-to-20
23-market
Stay With Us
TELEPHONE 1-800-910-6452 EMAIL
help_at_bigmarketresearch.com
5933 NE Win Sivers Drive,205, Portland, OR
97220United States
About PowerShow.com